Emerging Therapies in Pulmonary Fibrosis - PubMed
4 hours ago
- #Pulmonary Fibrosis
- #Emerging Therapies
- #Interstitial Lung Disease
- Interstitial lung diseases (ILD) are a diverse group of respiratory disorders with varying inflammation and fibrosis levels.
- Idiopathic pulmonary fibrosis (IPF) is the most common and severe type of ILD, characterized by chronic, progressive fibrosis of the alveolar interstitium.
- Current treatments for IPF include pirfenidone and nintedanib, which slow lung function decline but do not reverse existing damage.
- The FDA recently approved nerandomilast for IPF and progressive pulmonary fibrosis, while nintedanib is also approved for non-IPF ILDs.
- Research is focusing on new therapies that target the complex pathogenesis of pulmonary fibrosis to halt or reverse the disease.
- The article reviews the pathogenesis and prevalence of ILDs, current treatments, and emerging therapies in the field.